Literature DB >> 301897

Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney sarcomas.

G Y Gillespie, C B Hansen, R G Hoskins, S W Russell.   

Abstract

Highly purified suspensions of intratumoral T lymphocytes, recovered 11 and 13 days after induction of regressing or progressing Moloney sarcomas, were compared in their ability to lyse specifically the MSC cells used for tumor induction. Cytolytic activity, expressed in terms of lytic units/10(6) T cells, was similar for intratumoral T cell suspensions obtained 11 days after induction of either regressing (3.1 +/- 1.3 LU/10(6) T cells) or progressing (4.3 +/- 1.8) neoplasms. By 13 days post-induction, regressing tumors contained T lymphocytes with an increased cytolytic activity (11.1 +/- 4.5) whereas those from progressing tumors were strikingly less able to kill MSC cells (less than or equal to 0.2). This dramatic loss in cytotoxicity could not be attributed to errors associated with the enzymatic disaggregation method, inhibition by copurified endogenous tumor cells, or immunosuppression induced by viral infection. The changes in functional activity of intratumoral T lymphocytes from the two types of sarcoma appeared to be correlated with the stage of neoplasia. In this model system, cytolytic activity of T lymphocytes increased during spontaneous tumor regression whereas losses in cytotoxicity occurred coincident with the onset of inexorable progression.

Entities:  

Mesh:

Year:  1977        PMID: 301897

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Augmented induction of antitumor cells in vivo by cyclophosphamide fails to benefit antitumor resistance of the host.

Authors:  K Ryoyama; C Ryoyama
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Mechanisms of tumour rejection in the murine DBA/2-SL2 concomitant immunity system.

Authors:  D Characiejus; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Effector mechanisms of syngeneic anti-tumour responses in mice. I. Establishment and characterization of an exogenous IL-2-independent cytotoxic T-lymphocyte line specific for radiation-induced leukaemia RL male 1.

Authors:  K Kuribayashi; A Keyaki; S Sakaguchi; T Masuda
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

Review 4.  Immune surveillance and natural resistance: an evaluation.

Authors:  W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye.

Authors:  T L Knisely; J Y Niederkorn
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Membranes from T and B lymphocytes have different patterns of tyrosine phosphorylation.

Authors:  H S Earp; K S Austin; S C Buessow; R Dy; G Y Gillespie
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

7.  Tumors induced by murine sarcoma virus contain precursor cells capable of generating tumor-specific cytolytic T lymphocytes.

Authors:  J M Chapdelaine; F Plata; F Lilly
Journal:  J Exp Med       Date:  1979-06-01       Impact factor: 14.307

8.  Antigenic specificity of the cytolytic T lymphocyte response to murine sarcoma virus-induced tumors. III. Characterization of cytolytic T lymphocyte clones specific for Moloney leukemia virus-associated cell surface antigens.

Authors:  A Weiss; K T Brunner; H R MacDonald; J C Cerottini
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

9.  Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo.

Authors:  D H Lynch; R E Miller
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

10.  Quantitation and clonal isolation of cytolytic T lymphocyte precursors selectively infiltrating murine sarcoma virus-induced tumors.

Authors:  K T Brunner; H R MacDonald; J C Cerottini
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.